Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis

• Published in: Clinical breast cancer 2024-07, Vol.24 (5), p.411-420
• Main Authors: Pedersini, Rebecca, Buffoni, Martina, Petrelli, Fausto, Ghidini, Antonio, di Mauro, Pierluigi, Amoroso, Vito, Parati, Maria Chiara, Laini, Lara, Cosentini, Deborah, Schivardi, Greta, Ippolito, Giuseppe, Berruti, Alfredo, Laganà, Marta
• Format: Article
• Language: English
• Subjects: Ado-Trastuzumab Emtansine - adverse effects; Ado-Trastuzumab Emtansine - therapeutic use; Advanced breast cancer; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Female; Gastrointestinal adverse events; Gastrointestinal Diseases - chemically induced; Humans; Immunoconjugates - adverse effects; Immunoconjugates - therapeutic use; Nausea - chemically induced; Neoplasm Metastasis; Sacituzumab govitecan; Trastuzumab - adverse effects; Trastuzumab - therapeutic use; Trastuzumab deruxtecan
• ISSN: 1526-8209; 1938-0666; 1938-0666
• DOI: 10.1016/j.clbc.2024.04.003

Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with these drugs in clinical trials, a pooled analysis evaluating gastrointestinal adverse events (AEs) in patients with MBC treated with ADCs in clinical trials was performed. PubMed, Embase, and the Cochrane Library were searched from inception until May 2023 for phase II and III clinical trials reporting frequency and severity of gastrointestinal AEs during treatment with ADCs. Data were retrieved for nausea, vomiting, diarrhea, constipation, and abdominal pain: overall and grade 3-4 toxicity rates according to NCI-CTCAE were collected and expressed as proportions. A pre-specified subgroup analysis according to the agent was also carried out. Fourteen studies, comprising 5608 patients, were included in the analysis. Gastrointestinal AEs were frequently registered with SG and T-DXd. A significantly higher frequency of nausea (65.6% with SG, 75% with T-DXd), vomiting (43.7% with SG, 45% with T-DXd), and diarrhea (59.7% with SG, 29% with T-DXd) was noticed with these ADCs compared to TDM-1. Furthermore, diarrhea was more frequently associated with SG (grade 3 in 7.5% of patients), while constipation and abdominal pain were less common. Gastrointestinal AEs, notably nausea and diarrhea, were frequently reported by MBC patients treated with SG and T-DXd in clinical trials. Since these ADCs are administered continuously until disease progression or occurrence of unbearable AEs, gastrointestinal toxicity may have a negative impact on patient quality of life. Therefore, appropriate management of gastrointestinal AEs is mandatory to ensure treatment efficacy and adherence.